Author: admin

  • Webtoon Rebrands, Reorganizes North American Entertainment,

    Webtoon Rebrands, Reorganizes North American Entertainment,

    Webtoon Entertainment, the media company that spearheaded the mainstream embrace of webcomics, is rebranding and reorganizing the structure of its North American entertainment and intellectual property business as it aims to scale up the adaptations of its many titles.

    Effective immediately, Wattpad Webtoon Studios is morphing into Webtoon Productions, with David Madden elevated to president of the production company. He was previously head of global entertainment.

    Additionally, Maximilian Jo, general counsel and corporate secretary for Webtoon Entertainment, will take on a new concurrent role as vp, head of strategy for the company’s global IP business team. Meanwhile, Tina McIntyre has been named head of the newly-formed Webtoon Consumer Goods division, in a sign that the company will seek to monetize on the mountain of popular titles and IP it has created over the years.

    All three will report to Webtoon Entertainment chief strategy officer and head of global Webtoon Yongsoo Kim. 

    “Our platforms are a staple of Gen Z culture and our entertainment teams are working with some of the most exciting voices in Hollywood,” said Kim in a statement to The Hollywood Reporter. “We have hits on every global streaming platform, and people all over the world know that Webtoon means incredible content and passionate fandoms. Our rebrand as Webtoon Productions highlights our global Webtoon brand, signaling the incredible format, creator voices, and world-class IP that makes up our ecosystem. With the leadership of some of the most talented executives in the industry, we’re here to usher in a new era of entertainment and bring more Webtoon adaptations to the North American market.”

    As Webtoon Productions president, Madden will continue to oversee the development, production, and sales for the company’s U.S. and international feature film, TV, and animation slate of adaptations from Webtoon and Wattpad. He joined Wattpad Webtoon Studios in 2022 as head of global entertainment, developing hit projects that bridge traditional Hollywood and creator-driven storytelling. Madden previously acted as president of programming, entertainment networks at AMC Networks; president of Fox Television Studios; president of entertainment for the Fox Broadcasting Company; and president of television for Berlanti Productions. 

    In his new role, Jo will develop new strategic initiatives for Webtoon Productions and Webtoon Entertainment’s global IP ecosystem. He joined the company in 2021 as general counsel and was appointed to the concurrent role of corporate secretary in 2024. Before the exec joined Webtoon, he served as general counsel for Yeezy and general counsel & head of business & legal affairs for CJ Entertainment America, the U.S.-division of Korea’s largest entertainment conglomerate. 

    McIntyre, meanwhile, will oversee the company’s publishing business, including the Wattpad Webtoon Book Group of imprints, as well as the merchandising and licensing teams. (The company relaunched its online retail destination, Webtoon Shop, in 2024 as it began veering into merchandizing.) She previously held marketing and publishing roles at Scholastic; Little, Brown Books for Young Readers; and Hachette, leading campaigns for brands such as the Twilight SagaGoosebumps and Gossip Girl; developing digital strategies for Harry Potter; and working with bestselling authors James Patterson, Julie Andrews and Patrick McDonnell.

    Recent projects from Webtoon Productions include the Tubi hit movie Sidelined: The QB and Me, which premiered at number one and is said to have brought in the most new viewers for any title to date to the streaming service; international Netflix hit Mala Influencia; and Through My Window (A traves de mi ventana), one of Netflix’s most-watched non-English film of all time.

    Among its upcoming slate are Sidelined 2: Intercepted and Kissing is the Easy Part, both for Tubi, an animated take on its sensation Lore Olympus, and Death of a Pop Star, being developed by Diablo Cody and Mason Novick.

    Webtoon Productions Logo

    Courtesy of Webtoon

    Continue Reading

  • Blood of my Blood’ Trailer Teases Iconic Love Stories

    Blood of my Blood’ Trailer Teases Iconic Love Stories

    Starz has released the trailer for Outlander spinoff Blood of my Blood with Harriet Slater, Jamie Roy, Hermione Corfield and Jeremy Irvine at the helm.

    Premiering in the U.S. and Canada on Aug. 8, the prequel series details the love stories of the parents of Jamie Fraser (played by Sam Heughan) and Claire Randall (Caitriona Balfe), fan-favorite characters of the original show based on Diana Gabaldon’s book.

    The trailer for Outlander: Blood of my Blood that debuted on Thursday shows Corfield’s character, Julia Moriston, transported back to the 18th century after a car accident in the 1910s. In the rugged Scottish Highlands, Julia and Henry Beauchamp (Irvine), as well as Ellen MacKenzie (Slater) and Brian Fraser (Roy), must defy the forces that seek to tear them apart, intersecting the couples in surprising and unforeseen ways.

    Jeremy Irvine (“Henry Beauchamp”) and Hermione Corfield (“Julia Moriston Beauchamp”) in Outlander: Blood of my Blood.

    Starz

    Harriet Slater (“Ellen MacKenzie”) and Jamie Roy (“Brian Fraser”).

    Starz

    Jeremy Irvine (“Henry Beauchamp”) and Hermione Corfield (“Julia Moriston Beauchamp”).

    Starz

    The show also stars Tony Curran as Simon Fraser, Lord Lovat, Séamus McLean Ross as Colum MacKenzie, Sam Retford as Dougal MacKenzie, Rory Alexander as Murtagh Fitzgibbons Fraser, and Conor MacNeill as Ned Gowan.

    The standalone prequel series features new characters and stories, welcoming in viewers unfamiliar with the Outlander universe while also promising to provide origin stories of those from early seasons of the show — offering new perspectives that will change what viewers think they know.

    New episodes of Outlander: Blood of my Blood will air weekly on Fridays at 8:00 pm ET/PT on Starz in the U.S. and at 9:00 pm ET/PT in Canada.

    Matthew B. Roberts serves as showrunner and executive producer on Outlander: Blood of my Blood, with Ronald D. Moore, Maril Davis and Jim Kohlberg also serving as executive producers. The series is produced by Sony Pictures Television.

    Continue Reading

  • Tracking Insect and Bug Health in a Heartbeat From a Digital Camera

    Tracking Insect and Bug Health in a Heartbeat From a Digital Camera

    Newswise — In a world-first pilot study, researchers from the University of South Australia (UniSA) have used video footage of insects to extract their heart rates without touching or disturbing them.

    The innovation, published in the Archives of Insect Biochemistry and Physiology, could transform how scientists monitor the health and stress levels of arthropods, that account for more than 80% of animal species.

    Taking footage from smartphones, social media videos and digital cameras, the researchers used sophisticated signal processing methods to monitor the heart activity of ants, bees, caterpillars, spiders, grasshoppers and stick insects.

    Unlike mammals, arthropods have an open circulatory system in which blood fills the body cavity, bathing the internal organs and tissues. Their heart is located on the top (dorsal) side of their body in the abdomen.

    Led by UniSA PhD candidate Danyi Wang and her supervisor Professor Javaan Chahl, the study demonstrates that subtle body movements captured on standard digital or smartphone cameras can be analysed to reveal accurate and detailed cardiac activity in a range of insect species.

    Unlike traditional methods that require physical contact or immobilisation, this technique allows insects to remain free, without disrupting their natural behaviour.

    “Insects are vital to our ecosystems, and understanding their physiological responses to environmental change is essential,” Wang says.

    “Existing methods to measure insect’ vital signs are invasive, however. Our method preserves their natural behaviour while providing accurate insights into their heart activity.”

    The extracted heart rates closely matched the physiological ranges recorded via traditional techniques, validating the system’s accuracy.

    Senior author Prof Javaan Chahl says the system successfully captured heart rates across multiple insect species, detecting physiological differences influenced by factors such as wing morphology and temperature.

    “From ants with heart rates of around 50 beats per minute, to bees reaching 119bpm, our results consistently aligned with established reference values,” Prof Chahl says.

    “What’s exciting is that this was all achieved without attaching sensors or disturbing the insects in any way.”

    One of the most impressive validations came from caterpillar recordings, where the team compared their video-derived cardiac signals to data from infrared contact sensors in previous studies. The shapes and frequencies were almost identical.

    The study also revealed interesting inter-species variations. For example, spider heart rates varied significantly, reflecting differences between species rather than activity levels, since all subjects were at rest during filming.

    Advanced image processing techniques, including motion tracking algorithms and magnification, were applied to detect tiny movements associated with heartbeats. These signals were analysed using spectral filtering and transformed into frequency data to isolate the heart rate.

    According to Prof Chahl, the study marks an important step forward in insect research.

    “Non-invasive cardiac monitoring offers tremendous potential; not just for studying insect health, but also for understanding environmental stressors, pesticide effects, or even the wellbeing of social insects like ants and bees, where heart signals can provide insights into colony health and behaviour.”

    His team has previously used a similar technique with digital cameras to remotely extract cardiac signals in humans and wildlife.

    The researchers hope to test the system in the field and refine it by using machine learning to improve the accuracy across different body types and light conditions.

    “With more refinement, this could become a cost effective and valuable tool in the ecological research toolkit,” says Wang. “It gives us the ability to listen to the hearts of the smallest creatures without harming them.”

    ‘Extracting Cardiac Activity for Arthropods Using Digital Cameras: Insights from a Pilot Study’ is published in the Archives of Insect Biochemistry and Physiology. DOI:  10.1002/arch.70076

    Videos and images demonstrating the experiment are available at: public – Google Drive

     


    Continue Reading

  • Kylie Kelce finally shares which Kelce kid is family’s true tornado

    Kylie Kelce finally shares which Kelce kid is family’s true tornado

    Kylie Kelce opens up about her most out-of-control child 

    Kylie Kelce recently got candid and opened up about which of her daughters is the most “feral.”

    On the Thursday, July 10th episode of her Not Gonna Lie with Kylie Kelce podcast, the 33-year-old American podcaster talked about her four daughters, Wyatt, 5, Elliotte, 4, Bennett, 2, and Finnley, 3 months, whom she shares with husband Jason Kelce, the erstwhile American professional footballer.

    Referring to her second-born child, Kylie said, “My most feral child, for a very long time, thought for sure it was Elliotte. No one was going to rival her. She was going to take home the title no matter who came along, because she achieved the utmost level of feral. And then Bennett turned 2.”

    The mother of four went on to call her third daughter, Bennett, “tactical and feral” and admit that the combination is “more threatening and concerning.”

    “It’s more threatening and concerning. She is the child who is licking surfaces. It’s gross is what it is. And, also, she’s constantly scheming, so that’s kind of concerning. She will purposely do things when you’ve turned around, which seems f****** up,” Kylie Kelce remarked.


    Continue Reading

  • The most bullish S&P 500 forecast on Wall Street: 7,000 by year-end

    The most bullish S&P 500 forecast on Wall Street: 7,000 by year-end

    Continue Reading

  • Lancashire Lightning name squad for the Roses T20 at Emirates Old Trafford

    Lancashire Lightning name squad for the Roses T20 at Emirates Old Trafford





    Lancashire Lightning name squad for the Roses T20 at Emirates Old Trafford

    Read the latest squad news ahead of the Roses T20 between Lancashire Lightning and Yorkshire at Emirates Old Trafford on Friday evening (7.00pm)

    Steven Croft has named a 15-man squad ahead of the first Roses T20 of the season, which takes place tomorrow evening at Emirates Old Trafford – live on Sky Sports Cricket.

    All-rounder Tom Aspinwall returns to the First Team matchday squad after recovering from a side injury which has ruled him out for the last month.

    Aspinwall has been added to an otherwise unchanged squad from Lancashire’s trip to Edgbaston on Wednesday – with Liam Livingstone (hamstring) and Saqib Mahmood (knee) ruled out.

    Lightning head into the first of two Roses battles inside a week in second place, with seven wins from their opening 10 North Group games. Yorkshire sit second-bottom with three wins from 10.

    With 17,000 tickets now sold, an extremely limited number of seats remain for tomorrow evening’s Roses T20 – and can be purchased now by clicking here.

    Lancashire Lightning squad to face Yorkshire:

    Keaton Jennings (c), James Anderson, Tom Aspinwall, George Balderson, Jack Blatherwick, Jos Buttler, Chris Green, Tom Hartley, Matty Hurst, Michael Jones, Phil Salt, Mitch Stanley, Ashton Turner, Luke Wells, Luke Wood

    Match Preview

    How to follow:

    The match will be broadcast live and exclusive on Sky Sports Cricket, with ball-by-ball radio commentary from Emirates Old Trafford provided by BBC Radio Lancashire’s Scott Read on the BBC Sport website and app.

    For those unable to follow the action live, there will be regular updates on the Club’s social media channels and Match Centre, with highlights also posted on LancsTV.

    T20 Blast Tickets

    Come Together, Celebrate Together, STRIKE TOGETHER!

    GET TICKETS







    Continue Reading

  • Optics & Photonics News – Underwater Microscope Focuses on Coral Health

    Optics & Photonics News – Underwater Microscope Focuses on Coral Health

    A fluorescence image taken with the new microscope reveals individual microalgae (red dots) living within the tissue of a coral. [Image: Or Ben-Zvi]

    Scientists at the University of California, San Diego, USA, have built a diver-operated microscope that can reveal the complex biological processes that enable coral reefs to grow and thrive (Methods Ecol. Evol., doi: 10.1111/2041-210x.70078). The submersible imaging system offers new insights into the health and physiology of these vibrant natural habitats and could inform ongoing efforts to understand the mechanisms that cause coral bleaching.

    Photosynthetic efficiency

    Corals gain their reef-building energy from photosynthesis, but they lack the biological tools needed to drive this light-activated chemical reaction. Instead, they rely on microalgae living within their tissues to absorb sunlight and convert it into oxygen and energy-rich sugars.

    To assess the efficiency of this symbiotic process, the researchers incorporated an imaging technique into the microscope that measures the fluorescence produced by chlorophyll molecules within the algae. Images are captured first under ambient conditions and then again after the microalgae have been fully illuminated with an array of light-emitting diodes. The difference between the two fluorescent intensities provides a measure of the photosynthetic efficiency that can be mapped at the scale of individual algal cells. 

    Initial tests in the laboratory showed that the microscope can detect variations in the photosynthetic efficiency at much smaller scales than can be achieved with a commercial imaging tool. As an example, the researchers measured elevated conversion efficiencies close to the mouths of coral polyps around 1 mm across, a detail that could not be resolved with the commercial system. Further lab-based experiments revealed how corals growing in deeper waters can achieve higher photosynthetic efficiencies than those living in the sunlit shallows.

    Seeing coral in a new light

    Scuba diver with large device over coral

    Researcher diving with new submersible microscope to image coral. [Image: Or Ben-Zvi / Scripps Oceanography, University of California San Diego]

    To investigate the microscope’s underwater performance, marine biologist Or Ben-Zvi imaged corals off the coast of Maui, Hawaii, USA, that have two distinct morphologies. One of these variants was found to be more efficient at converting sunlight into energy, which the researchers suggest could result from their structural differences, varying light conditions across the reef, or a change in the genetic identity of the microalgae.

    The submersible microscope also captures full-color pictures and videos, as well as more general fluorescence images and movies with submicron resolution. Color-coding the fluorescence images provides a clear view of individual microalgae residing within the coral tissue. Ben-Zvi was also able to record the rapid contraction of a polyp’s tentacles in response to a passing particle.

    The researchers hope that the data collected by the microscope could provide early warning signs of damage to these diverse ecosystems, which are under threat from warming seas and poor environmental conditions. “We can get a lot of information about the health of these corals without needing to interrupt nature,” says Ben-Zvi.

    Continue Reading

  • EC proposes rules for chemically recycled content in plastic bottles

    EC proposes rules for chemically recycled content in plastic bottles

    The European Commission (EC) has opened a public consultation on proposed regulations for assessing, validating, and documenting recycled material in single-use plastic beverage bottles, including chemically recycled material.

    The commission indicates that these regulations will support chemical recycling within the EU and assist businesses in achieving their recycled material targets established under the Single-Use Plastics Directive.

    These potential regulations are a component of the new ‘Action Plan for the EU Chemicals Sector’, which seeks to bolster the industry’s competitiveness and facilitate its shift towards safe, sustainable, and innovative chemical manufacturing.

    With rising quantities of plastic waste in the EU, the commission underscores the pressing need to enhance plastic waste collection, sorting, and recycling to meet recycling objectives.

    Although mechanical recycling is favoured for its reduced environmental impact and energy efficiency, chemical recycling is acknowledged as an important alternative when mechanical methods are impractical or when stricter quality requirements (as in food packaging) are necessary.

    The proposed regulations aim to ensure clarity in calculating the proportion of chemically recycled material in new single-use plastic bottles.

    The calculation methodology follows the ‘fuel-use excluded’ allocation rule. This means that any waste utilised for fuel production or energy recovery cannot be considered as recycled content, in accordance with the definition of ‘recycling’ outlined in the Waste Framework Directive.

    The commission stated that the rules are designed to strike a balance between transparency and reducing the administrative burden on companies and national authorities.

    Annual third-party verification will be mandated for the most intricate phases of the value chain, specifically during chemical recycling.

    Small and medium-sized enterprises (SMEs) will benefit from less stringent requirements, needing this validation every three years.

    Businesses will be responsible for verifying their partners’ self-declarations while national authorities will carry out risk-based inspections.

    This is reportedly the EU’s inaugural set of regulations specifically addressing chemically recycled material.

    The assessment methodology is designed to act as a template for future regulations on recycled material in other sectors such as packaging, automotive, and textiles.

    In a statement, the European Commission said: “By incentivising investments and supporting new recycling technologies, the rules will boost the competitiveness of both the EU chemical industry and manufacturers that use plastics in their production, helping to establish Europe as a leader in sustainable innovation.

    Continue Reading

  • REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

    REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

    • Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin
    • REGENXBIO’s next-generation investigational gene therapy, RGX-202, is the only microdystrophin construct that includes the CT domain
    • Findings support the positive functional data seen in Phase I/II AFFINITY DUCHENNE® trial of RGX-202

    ROCKVILLE, Md., July 10, 2025 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal (CT) domain to a microdystrophin construct without the CT domain. The results, which were published in peer-reviewed journal Molecular Therapy Methods and Clinical Development, showed that the microdystrophin with the CT domain improved functional benefit compared to the microdystrophin without, supporting the potential of RGX-202 to drive functional improvements in patients with Duchenne Muscular Dystrophy.

    RGX-202 is the only investigational or approved microdystrophin gene therapy candidate for the treatment of Duchenne muscular dystrophy (Duchenne) that includes the CT domain, a key portion of dystrophin, making it the closest to naturally occurring dystrophin.

    “We specifically designed RGX-202 differently from other gene therapies with the goal of providing improved outcomes for patients, and this research further validates the potential therapeutic advantage of adding the CT domain and its importance in preventing the muscle breakdown associated with functional decline in Duchenne,” said Olivier Danos, Ph.D., Chief Scientific Officer of REGENXBIO. “The positive interim results we’ve seen in the Phase I/II AFFINITY DUCHENNE® trial are reinforced by this preclinical research demonstrating how the novel construct of RGX-202 protects against muscle damage and supports the potential for durable, functional benefit for patients.”

    “AAV gene therapy holds great promise for Duchenne, and the community is in need of treatment options that have the potential to improve function and quality of life for patients,” said Michael Kelly, Ph.D., Chief Scientific Officer, CureDuchenne. “The CT domain is a critical part of the large DMD gene and these preclinical results highlight its role in muscle health. With the science behind the novel microdystrophin construct of RGX-202, combined with the interim safety and efficacy profile seen to date in clinic, I am very encouraged by the potential of RGX-202 to be a meaningful, differentiated gene therapy for the community.”

    In this paper, titled “Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain,” two AAV vectors, one encoding a microdystrophin protein with the CT domain and one encoding an otherwise equivalent microdystrophin protein without the CT domain, were evaluated across three studies in mdx mice, a preclinical model of Duchenne, to measure muscle force, protein levels, and protection from contraction-induced muscle injury.  

    Compared to the microdystrophin without the CT domain, the microdystrophin that included the CT domain was found to be maintained at higher levels in transduced muscles, recruited the dystrophin-associated protein complex more effectively to the muscle membrane, and increased muscle force and resistance to damage in mice lacking dystrophin. These are key factors in supporting the preservation of muscle health, as muscle damage leads to disease progression in Duchenne.

    These findings indicate that incorporation of the CT domain enhances the microdystrophin design by allowing for higher levels of microdystrophin to accumulate in the muscle – primarily attributed to the longer half-life of the extended microdystrophin – and may improve the functional benefit of microdystrophin gene replacement. Interim results from the Phase I/II AFFINITY DUCHENNE clinical trial of RGX-202 reported in June 2025 show that RGX-202 demonstrated consistent evidence of positively changing the disease trajectory of patients with Duchenne and a favorable safety profile.

    REGENXBIO is enrolling participants in the pivotal portion of the Phase I/II/III AFFINITY DUCHENNE trial of RGX-202 and expects to submit a Biologics License Application (BLA) using the accelerated approval pathway in mid-2026. 

    About RGX-202
    RGX-202 is a potential best-in-class investigational gene therapy designed for improved function and outcomes in Duchenne. RGX-202 is the only gene therapy approved or in late-stage development for Duchenne with a differentiated microdystrophin construct that encodes key regions of naturally occurring dystrophin, including the C-Terminal (CT) domain.

    Additional design features such as codon optimization may potentially improve gene expression, increase protein translation efficiency and reduce immunogenicity. RGX-202 is designed to support the delivery and targeted expression of microdystrophin throughout skeletal and heart muscle using the NAV® AAV8 vector and a well-characterized muscle-specific promoter (Spc5-12). RGX-202 is manufactured by REGENXBIO using its proprietary, high-yielding NAVXpress® suspension-based platform process.

    About Duchenne Muscular Dystrophy
    Duchenne is a severe, progressive, degenerative muscle disease, affecting 1 in 3,500 to 5,000 boys born each year worldwide. Duchenne is caused by mutations in the Duchenne gene which encodes for dystrophin, a protein involved in muscle cell structure and signaling pathways. Without dystrophin, muscles throughout the body degenerate and become weak, eventually leading to loss of movement and independence, required support for breathing, cardiomyopathy and premature death.

    ABOUT REGENXBIO Inc.
    REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO’s AAV platform, including those receiving Novartis’ ZOLGENSMA®. REGENXBIO’s investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

    FORWARD-LOOKING STATEMENTS
    This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on Form 10-K for the year ended December 31, 2024, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC’s website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Zolgensma® is a registered trademark of Novartis AG. All other trademarks referenced herein are registered trademarks of REGENXBIO.

    Contacts:
    Dana Cormack
    Corporate Communications
    [email protected]  

    Investors:
    George E. MacDougall
    Investor Relations
    [email protected] 

    SOURCE REGENXBIO Inc.

    Continue Reading

  • Women’s Giro d’Italia: Lorena Wiebes claims second stage win as Marlen Reusser keeps overall lead

    Women’s Giro d’Italia: Lorena Wiebes claims second stage win as Marlen Reusser keeps overall lead

    Lorena Wiebes sprinted to victory on the fifth stage of the Women’s Giro d’Italia, her second win of the race so far.

    A group of 15 broke away from the peloton with 53km to go and on an almost entirely flat ride from Mirano and Monselice, pushed all the way to the finish line, with Wiebes just pipping her Dutch compatriot Marianne Vos.

    Germany’s Liane Lippert finished third and Switzerland’s Marlen Reusser came fifth to hold on to her overall lead.

    Movistar’s Reusser has a 16-second advantage over last year’s champion, Elisa Longo Borghini of Italy, who is second.

    Great Britain’s Anna Henderson remains in 13th, more than 11 minutes behind the leader, after a difficult fourth stage.

    “The whole team did really well. First, we controlled the breakaway with the team, and then we put the race in the gutter a bit together with UAE Team ADQ,” said SD Worx-Protime’s Wiebes.

    “The peloton broke and we had to finish it off, and the girls did amazing again, with Barbara [Guarischi] and Lotte [Kopecky] leading me out, it’s really great to have them.”

    It is Wiebes’ second stage win in the space of three days, having claimed stage three on Tuesday.

    Friday’s sixth stage presents a different challenge with a hilly 145km route from Bellaria-Igea Marina to Terre Roveresche.

    Continue Reading